Newsfeeds - Spark Newswire

1 minute read

Viatris Q4 Sales $4.33B Miss $4.35B Estimate

Today, 8:52 PM

Viatris (NASDAQ:VTRS) reported quarterly sales of $4.33 billion which missed the analyst consensus estimate of $4.35 billion by 0.46 percent. This is a 119.38K percent increase over sales of $3.62 million the same

VTRS

10 minute read

Earnings Scheduled For February 28, 2022

By Benzinga Insights

Today, 8:52 PM

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.

AAON

5 minute read

M&A
News

Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to $3.335B in Stock and Cash

By Charles Gross

Today, 8:52 PM

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that it has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd.

VTRS

3 minute read

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight

By Shanthi Rexaline

Today, 8:52 PM

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.

ACAD

1 minute read

A Bullish Sign Appears On Viatris’s Chart

By Benzinga Insights

Today, 8:52 PM

If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

VTRS

4 minute read

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More

By Shanthi Rexaline

Today, 8:52 PM

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish.

ABBV

2 minute read

Viatris Highlights Its First To Receive FDA Approval For A Generic Restasis To Treat Dry Eye Disease

By Benzinga Newsdesk

Today, 8:52 PM

Approval Reinforces Viatris' Steadfast Commitment to Breaking Down Barriers and Expanding Access to Complex Generic Products Milestone Achieved After Decade-Long Investment in Product Development and Numerous Legal

VTRS

3 minute read

FDA
News

UPDATE: Viatris Manufactures Generic Restasis

By Benzinga Newsdesk

Today, 8:52 PM

FDA Approves First Generic Of Restasis. BZ NOTE: AbbVie Manufactures Restasis FDA Approves First Generic of Restasis SILVER SPRING, Md., Feb. 2, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration has

ABBV

3 minute read

FDA
News

FDA Approves First Generic Of Restasis. BZ NOTE: AbbVie Manufactures Restasis

By Benzinga Newsdesk

Today, 8:52 PM

FDA Approves First Generic of Restasis SILVER SPRING, Md., Feb. 2, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration has approved the first generic of Restasis (cyclosporine ophthalmicFDA Approves First Generic of Restasis

ABBV

2 minute read

News

10 Worst Performing S&P 500 Stocks Of 2021

By Wayne Duggan

Today, 8:52 PM

The S&P 500 delivered one of its best years in recent history in 2021, gaining more than 27%. Most U.S. investors had a lot of winners in their portfolios this year, but some stocks certainly performed better than others. Here’s a look at the 10 worst-performing stocks in the entire S&P 500 in 2021.

ATVI